Neupulse has received £2.5 million in funding to bring to market the first wearable device designed to address Tourette Syndrome and other tic disorders. The University of Nottingham spinout recently finalized a working prototype that stimulates the median nerve in the wrist, resulting in a decrease in the frequency of tics in individuals with TS. The company is seeking regulatory approval in the UK, Europe, and the USA. In 2023, clinical trials demonstrated that the Neupulse device lowered tics by over 25 percentile. Eos Advisory of Scotland led the seed investment, with participation from US investors.
CEO Paul Cable said, “Our mission is to drastically reduce tics with an easy-to-use wearable device that will be transformative to the lives of affected individuals.” Neupulse aims to introduce a treatment for Tourette’s Syndrome that is an alternative to medication and cognitive behavior therapy. The company hopes it can make Neupulse available to the Tourette Syndrome community globally in the years ahead.
Eos Advisory Partner Ana Stewart sees investing in science-based companies and founders as an opportunity to add value beyond the investment to provide products that positively impact the lives of people worldwide. Neupulse presents such an opportunity, Stewart said, given the nascent technology could offer benefits for many other neural conditions in the future.
Neupulse has received £2.5 million in funding to bring to market the first wearable device designed to address Tourette Syndrome and other tic disorders. The University of Nottingham spinout recently finalized a working prototype that stimulates the median nerve in the wrist, resulting in a decrease in the frequency of tics in individuals with TS. The company is seeking regulatory approval in the UK, Europe, and the USA. In 2023, clinical trials demonstrated that the Neupulse device lowered tics by over 25 percentile. Eos Advisory of Scotland led the seed investment, with participation from US investors.
CEO Paul Cable said, “Our mission is to drastically reduce tics with an easy-to-use wearable device that will be transformative to the lives of affected individuals.” Neupulse aims to introduce a treatment for Tourette’s Syndrome that is an alternative to medication and cognitive behavior therapy. The company hopes it can make Neupulse available to the Tourette Syndrome community globally in the years ahead.
Eos Advisory Partner Ana Stewart sees investing in science-based companies and founders as an opportunity to add value beyond the investment to provide products that positively impact the lives of people worldwide. Neupulse presents such an opportunity, Stewart said, given the nascent technology could offer benefits for many other neural conditions in the future.